Steven Cohen isn't afraid of volatility — and his latest moves show he's diving headfirst into small-cap biotech. The billionaire hedge fund manager's Point72 Asset Management has built new stakes in two clinical-stage companies, betting that their breakthroughs in genetic and antibody therapies could deliver outsized returns.
The timing is notable: both stocks have been on a tear in recent weeks, giving Cohen's portfolio a dose of biotech momentum.
